Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1

Faculty: Michael Collins

This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies for implementing and interpreting genetic testing, and evaluate emerging therapies—such as calcilytics—that target CaSR mutations. By improving diagnostic accuracy, enabling timely and evidence-based interventions, and improving knowledge of emerging treatments, this activity aims to advance clinical outcomes for patients with ADH1.